Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Company Announcement - Genmab A/S reported worldwide net trade sales of DARZALEX (daratumumab) totaling USD 3,237 million in Q1 2025, with USD 1,829 million from the U.S. and USD 1,409 million from the rest of the world [1][5] - Genmab receives royalties on the worldwide net sales of DARZALEX, which includes both intravenous and subcutaneous products, under an exclusive license agreement with Johnson & Johnson [1][5] About Genmab - Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve patient lives, with a vision to transform cancer treatment by 2030 [2] - The company has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators [2] Company Background - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, and has a presence in North America, Europe, and Asia Pacific [3]